Analyst Activity – HC Wainwright Reiterates Buy on Anthera Pharmaceuticals (NASDAQ:ANTH)

0

Analyst Ratings For Anthera Pharmaceuticals (NASDAQ:ANTH)

Today, HC Wainwright reiterated its Buy rating on Anthera Pharmaceuticals (NASDAQ:ANTH) with a price target of $3.00.

There are 3 hold ratings, 2 buy ratings on the stock.

The current consensus rating on Anthera Pharmaceuticals (NASDAQ:ANTH) is Hold (Score: 2.40) with a consensus target price of $5.89 per share, a potential 359.96% upside.

Some recent analyst ratings include

  • 9/19/2017-HC Wainwright Reiterated Rating of Buy.
  • 8/11/2017-Jefferies Group LLC Reiterated Rating of Hold.
  • 12/29/2016-Citigroup Inc. was Downgraded by analysts at Citigroup Inc. from a “Buy ” rating to a ” Neutral” rating.
  • 12/28/2016-SunTrust Banks, Inc. was Downgraded by analysts at SunTrust Banks, Inc. from a “Buy ” rating to a ” Hold” rating. They now have a $8.00 price target on the stock, up previously from $48.00 .
  • 6/20/2016-FBR & Co Reiterated Rating of Hold.

Recent Insider Trading Activity For Anthera Pharmaceuticals (NASDAQ:ANTH)
Anthera Pharmaceuticals (NASDAQ:ANTH) has insider ownership of 5.60% and institutional ownership of 27.26%.

  • On 9/7/2017 John Craig Thompson, CEO, bought 10,400 with an average share price of $1.43 per share and the total transaction amounting to $14,872.00. View SEC Filing
  • On 9/7/2017 Paul F Truex, Director, bought 5,000 with an average share price of $1.34 per share and the total transaction amounting to $6,700.00. View SEC Filing
  • On 11/13/2015 Colin Hislop, insider, sold 12,500 with an average share price of $5.31 per share and the total transaction amounting to $66,375.00. View SEC Filing
  • On 11/11/2015 Colin Hislop, Insider, sold 5,000 with an average share price of $5.38 per share and the total transaction amounting to $26,900.00. View SEC Filing
  • On 10/12/2015 Debra Odink, CTO, sold 1,205 with an average share price of $6.15 per share and the total transaction amounting to $7,410.75. View SEC Filing
  • On 6/24/2013 David E Thompson, Director, bought 12,500 with an average share price of $0.53 per share and the total transaction amounting to $6,625.00. View SEC Filing
  • On 5/31/2013 Bogdan Dziurzynski, Director, bought 1,250 with an average share price of $0.59 per share and the total transaction amounting to $737.50. View SEC Filing

Recent Trading Activity for Anthera Pharmaceuticals (NASDAQ:ANTH)
Shares of Anthera Pharmaceuticals closed the previous trading session at with shares trading hands.